Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Immunotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1613 results found since Jan 2013.
Tumour adaptation to immune factors: old and new ideas for cancer immunotherapy
Can J Physiol Pharmacol. 2023 Sep 20. doi: 10.1139/cjpp-2023-0083. Online ahead of print.ABSTRACTThe tumour is fully functional in the zone of action of immune mediators. Moreover, the tumour needs immune system mediators to survive. "Adaptation" refers to a tumour's ability to withstand the effect of harmful elements. This gives birth to a new form of antitumour therapy: blocking tumour adaptability pathways. In this review, we will look at (i) tumour adaptation mechanisms as a result of pro-tumour immunoediting, (ii) how understanding tumour-adaptive mechanisms has led to ideas for developing cancer immunotherapies, and ...
Source: Canadian Journal of Physiology and Pharmacology - September 20, 2023 Category: Drugs & Pharmacology Authors: I Yu Malyshev O P Budanova L V Kuznetsova Source Type: research
Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy
Annu Rev Pharmacol Toxicol. 2023 Sep 18. doi: 10.1146/annurev-pharmtox-051920-095416. Online ahead of print.ABSTRACTToday's challenge for precision medicine involves the integration of the impact of molecular clocks on drug pharmacokinetics, toxicity, and efficacy, toward personalized chronotherapy. Meaningful improvements of tolerability and/or efficacy of medications through proper administration timing have been confirmed over the past decade for immunotherapy and chemotherapy against cancer, as well as for commonly used pharmacological agents in cardiovascular, metabolic, inflammatory, and neurological conditions. Expe...
Source: Pharmacological Reviews - September 18, 2023 Category: Drugs & Pharmacology Authors: Francis A L évi Alper Okyar Eva Hadadi Pasquale F Innominato Annabelle Ballesta Source Type: research
Role and clinical significance of immunogenic cell death biomarkers in chemoresistance and immunoregulation of head and neck squamous cell carcinoma
Biomed Pharmacother. 2023 Sep 16;167:115509. doi: 10.1016/j.biopha.2023.115509. Online ahead of print.ABSTRACTHead and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies in the whole world, with little improvement in the 5-year survival rate due to the occurrence of chemoresistance. With the increasing interests in tumor immune microenvironment, immunogenic cell death (ICD)-induced chemotherapy has shown promising results in enhancing sensitivity to immune checkpoint inhibitors (ICI) and improving the efficiency of tumor immunotherapy. This review summarizes the role of key ICD biomarkers and their...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 18, 2023 Category: Drugs & Pharmacology Authors: Xuanyu Zhang Chao Shang Xue Qiao Yan Guo Source Type: research
Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy
Annu Rev Pharmacol Toxicol. 2023 Sep 18. doi: 10.1146/annurev-pharmtox-051920-095416. Online ahead of print.ABSTRACTToday's challenge for precision medicine involves the integration of the impact of molecular clocks on drug pharmacokinetics, toxicity, and efficacy, toward personalized chronotherapy. Meaningful improvements of tolerability and/or efficacy of medications through proper administration timing have been confirmed over the past decade for immunotherapy and chemotherapy against cancer, as well as for commonly used pharmacological agents in cardiovascular, metabolic, inflammatory, and neurological conditions. Expe...
Source: Annual Review of Pharmacology and Toxicology - September 18, 2023 Category: Drugs & Pharmacology Authors: Francis A L évi Alper Okyar Eva Hadadi Pasquale F Innominato Annabelle Ballesta Source Type: research
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Biomed Pharmacother. 2023 Sep 14;167:115514. doi: 10.1016/j.biopha.2023.115514. Online ahead of print.ABSTRACTProgrammed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed on the surface of immune cells. As a receptor and immune checkpoint, PD-1 can bind to programmed death ligand-1/programmed death ligand-2 (PD-L1/PD-L2) in tumor cells, leading to tumor immune evasion. Anti-PD-1 and anti-PD-L1 are important components in tumor immune therapy. PD-1 is also expressed as an intrinsic variant (iPD-1) in cancer cells where it plays important roles in malignant progression...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 16, 2023 Category: Drugs & Pharmacology Authors: Muhua Chen Lei Bie Jieer Ying Source Type: research
Inhibiting autophagy to boost antitumor immunity with tetramethylpyrazine-loaded and PD-L1-targeting Liposomal Nanoparticles
Eur J Pharm Sci. 2023 Sep 9:106581. doi: 10.1016/j.ejps.2023.106581. Online ahead of print.ABSTRACTCancer immunotherapy has been recognized as a revolutionary breakthrough and has yielded impressive results. However, a major challenge facing immunotherapy is its limited efficacy, which may be largely due to the inadequate infiltration of immune cells into the tumor microenvironment (TME). Autophagy inhibition has been identified to enhance the recruitment of immune cells into the tumor by upregulating the expression and secretion of chemokines. Here, we verified a novel autophagy inhibitor tetramethylpyrazine (TMP) from na...
Source: European Journal of Pharmaceutical Sciences - September 11, 2023 Category: Drugs & Pharmacology Authors: Fei Zhou Xiaojiaoyang Li Kexin Jia Fanghong Li Xiaoyong Xue Jia Liu Jiaorong Qu Runping Liu Source Type: research
Involvement of CHRNA6 in the Immune Response in Lung Squamous Cell Carcinoma and its Potential as a Drug Target for the Disease
CONCLUSION: CHRNA6 may be associated with immune infiltration in LUSC and affects patient prognosis and immunotherapeutic response by regulating immune cells and immune pathways. In addition, adavosertib may be a potential drug for the treatment of LUSC.PMID:37680128 | DOI:10.2174/1381612829666230901143203
Source: Current Pharmaceutical Design - September 8, 2023 Category: Drugs & Pharmacology Authors: Fengyu Zhang Meidi Zhang Xin Yuan Yulian Tao Ju Wang Source Type: research
